Ignite Creation Date:
2025-12-25 @ 2:00 AM
Ignite Modification Date:
2026-02-11 @ 3:20 PM
Study NCT ID:
NCT00473694
Status:
COMPLETED
Last Update Posted:
2019-03-19
First Post:
2007-05-14
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
P05945
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None